- Amdocs has forecasted its 3Q adjusted EPS to be between $1.57 and $1.63, below the estimated $1.67.
- Revenue is expected to be between $1.24 billion and $1.28 billion, around the $1.26 billion estimate.
- For the year forecast, Amdocs sees adjusted EPS rising between +7% and +11%.
- Annual revenue, as reported, is predicted to rise between +1.6% and +3.6%.
- Market sentiments towards Amdocs is positive, with 5 buys, 2 holds, and 0 sell ratings.
A look at Amdocs Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores for Amdocs Ltd, the company shows a balanced outlook across key factors. With a score of 3 out of 5 in Value, Dividend, Growth, Resilience, and Momentum, Amdocs is positioned with moderate strength in various aspects. Amdocs Limited, a prominent provider of information system solutions to telecommunications companies globally, displays stability and consistency in its overall performance.
Amdocs Ltd‘s steady scores across Value, Dividend, Growth, Resilience, and Momentum indicate a well-rounded profile for the company’s long-term prospects. As a supplier of integrated customer care and billing systems to major telecom firms, Amdocs demonstrates reliability and a solid foundation in its operations. The consistent ratings reflect Amdocs’ ability to maintain a competitive position and withstand market fluctuations effectively.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
